Covid-19
Cohort Study | Analysis of Rituximab use and COVID-19 hospitalization or death in patients with multiple sclerosis
19 Jan, 2023 | 14:22h | UTC
Commentary on Twitter
Patients with MS on rituximab vaccinated for #COVID19 6 months before or after their last infusion had a much lower risk of COVID hospitalization – 1.4 vs 3.6 per 100 among unvaccinated people. https://t.co/am6hdSidMT
— JAMA Network Open (@JAMANetworkOpen) December 28, 2022
Report | The COVID-19 pandemic and the future of telemedicine
18 Jan, 2023 | 14:28h | UTCNews Release: New report looks to the future of telemedicine – Imperial College London
M-A | Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection
18 Jan, 2023 | 14:27h | UTCNews Release: COVID-19 infection at any time during pregnancy boosts mother’s risk of death – BMJ
Commentary: Getting COVID in Pregnancy Greatly Raises a Woman’s Odds for Death – HealthDay
M-A | Increased risk of acute myocardial infarction after COVID-19 recovery
17 Jan, 2023 | 13:22h | UTC
Impact of SARS-CoV-2 variants on inpatient clinical outcome
17 Jan, 2023 | 13:21h | UTCImpact of SARS-CoV-2 variants on inpatient clinical outcome – Clinical Infectious Diseases
WHO updates COVID-19 guidelines on masks, treatments and patient care
15 Jan, 2023 | 20:44h | UTCWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
WHO Updated Guidelines:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
Review | Long COVID: major findings, mechanisms and recommendations
15 Jan, 2023 | 20:34h | UTCLong COVID: major findings, mechanisms and recommendations – Nature Reviews Microbiology
A survey of COVID-19 vaccine acceptance across 23 countries in 2022
15 Jan, 2023 | 20:33h | UTCA survey of COVID-19 vaccine acceptance across 23 countries in 2022 – Nature Medicine
News Release: Global COVID-19 vaccine acceptance rising but hesitancy remains – London School of Hygiene & Tropical Medicine
Commentary on Twitter
The third annual iteration of a survey assessing vaccine confidence in 23 countries shows the overall willingness to accept a COVID-19 vaccine has increased, although results were heteregeous across countries, according to a @NatureMedicine paper. https://t.co/0EkMH7oRdn pic.twitter.com/bLc98F9AYt
— Nature Portfolio (@NaturePortfolio) January 13, 2023
RCT | Fluvoxamine no better than placebo in outpatients with mild to moderate COVID-19
15 Jan, 2023 | 20:37h | UTCEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Author Interview: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Commentary: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Commentary on Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Retrospective Study | Most patients with long Covid developed after mild infection get better within a year
13 Jan, 2023 | 13:42h | UTCLong covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study – The BMJ
News Release: Most long COVID effects resolve within a year after mild infection, finds study- British Medical Journal
Commentary: Long COVID After Mild Infection? It Fades Within a Year – HealthDay
Study identified six clusters of patients with long COVID, with distinct profiles of phenotypic abnormalities
13 Jan, 2023 | 13:40h | UTCGeneralisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes – eBioMedicine
RCT | Early treatment with Molnupiravir did not reduce hospitalizations in high-risk adults with COVID-19
12 Jan, 2023 | 13:24h | UTCCommentaries:
Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery – CIDRAP
The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
12 Jan, 2023 | 13:26h | UTC
Statement | Pre-procedure and pre-admission COVID-19 testing no longer recommended for asymptomatic patients
11 Jan, 2023 | 14:36h | UTCRecommendation Statement: Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: Challenges and considerations – Infection Control & Hospital Epidemiology
Commentary: Infectious disease board recommends hospitals stop screening asymptomatic patients for Covid-19 – STAT
Circulating spike protein detected in post–COVID-19 mRNA vaccine myocarditis
11 Jan, 2023 | 14:30h | UTCCirculating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis – Circulation
Commentary: Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine – News Medical
Review | Durability of vaccine-induced and natural immunity against COVID-19
11 Jan, 2023 | 14:29h | UTC
RCT | VV116 vs. Nirmatrelvir–Ritonavir for oral treatment of Covid-19
9 Jan, 2023 | 14:50h | UTCVV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 – New England Journal of Medicine
Commentaries:
Study could pave way for new antiviral, as China grapples with Covid wave – STAT
Chinese oral COVID-19 drug equally effective with Paxlovid: study
VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19 – HealthDay
Commentary on Twitter
In a Chinese trial involving participants with symptomatic mild-to-moderate Covid-19, VV116 (an oral analogue of remdesivir) was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery.
Read the full study: https://t.co/zckTB3Rvb9 pic.twitter.com/0TVF7hEXjP
— NEJM (@NEJM) December 28, 2022
The WHO estimates of excess mortality associated with the COVID-19 pandemic
9 Jan, 2023 | 14:48h | UTCThe WHO estimates of excess mortality associated with the COVID-19 pandemic – Nature
Commentary: Pandemic’s Two-Year Global Death Toll May Be Close to 15 Million – HealthDay
RCT | Twice-daily oral zinc in the treatment of patients with COVID-19.
12 Dec, 2022 | 12:48h | UTC
M-A | Efficacy of awake prone positioning in patients with covid-19 related hypoxemic respiratory failure.
9 Dec, 2022 | 13:31h | UTCEditorial: Awake prone positioning and covid-19 – The BMJ
News Release: Lying prone reduces need for breathing tube in covid-19 patients – BMJ Newsroom
Commentary: Study shows prone position limited breathing tubes for COVID-19 patients – CIDRAP
Commentary on Twitter
Lying prone reduces need for breathing tube in #covid patients, but evidence for the effect on death or other outcomes is inconclusive, finds new research in @bmj_latest by @kenparhar and colleagues
? ▶️ https://t.co/yodPDxbeuI pic.twitter.com/cHAWx0w00v— BMJ (@bmj_company) December 8, 2022
SR | Efficacy and safety of COVID‐19 vaccines.
8 Dec, 2022 | 13:04h | UTCEfficacy and safety of COVID‐19 vaccines – Cochrane Library
Summary: What are the benefits and risks of vaccines for preventing COVID-19? – Cochrane Library
Commentary: Are COVID-19 vaccines effective and safe? New Cochrane evidence – Evidently Cochrane
M-A | Face masks to prevent transmission of respiratory infections.
8 Dec, 2022 | 12:42h | UTC
FDA | No useful monoclonal antibody treatments left against new COVID-19 variants.
7 Dec, 2022 | 14:31h | UTCFDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants – HealthDay
Related: Study shows Omicron sublineage BQ.1.1 is resistant to all monoclonal antibodies.
M-A | Higher vs. lower dose corticosteroids for severe to critical COVID-19.
6 Dec, 2022 | 14:00h | UTC
Case-control study | Effectiveness of COVID-19 vaccines against infection and mortality in children in Argentina.
2 Dec, 2022 | 14:36h | UTC